Rivaroxaban Versus Standard of Care for Patients With Excessive Atrial Ectopy or Short Atrial Runs and High Embolism Risk
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 550 participants.
Also called NCT05487950
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 550 participants
- Registry
-
NCT05487950
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT05487950. Randomized; no masking; primary purpose treatment. Start 2023-04-05 (anticipated); primary completion 2027-04-05 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Rivaroxaban Versus Standard of Care for Patients With Excessive Atrial Ectopy or Short Atrial Runs and High Embolism Risk
- Acronym
- SHORT RUN AF
- Condition
- Excessive Supraventricular Ectopies or Short Atrial Runs (ESVEA)
- Intervention (Drug)
- Rivaroxaban group
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
Record details
- Record id
cardio:ct-nct05487950- Content hash
8018cfa33990b7a06de3fbf5ba2db0a8f6d19016b159b10670d65e3d0c6b4c3c